208 related articles for article (PubMed ID: 34689007)
1. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
Nguyen H; Ahmed K; Luo W; Flint J; Giles I
Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
3. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
4. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
Singh N; Li CI
Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
[TBL] [Abstract][Full Text] [Related]
5. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.
Mouyis M; Flint JD; Giles IP
Semin Arthritis Rheum; 2019 Apr; 48(5):911-920. PubMed ID: 30220537
[TBL] [Abstract][Full Text] [Related]
6. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
7. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
8. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
10. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
Shimada H; Kameda T; Kanenishi K; Miyatake N; Nakashima S; Wakiya R; Kato M; Miyagi T; Mansour MMF; Hata T; Kadowaki N; Dobashi H
Clin Rheumatol; 2019 May; 38(5):1453-1458. PubMed ID: 30729372
[TBL] [Abstract][Full Text] [Related]
11. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.
Roodenrijs NMT; Hamar A; Kedves M; Nagy G; van Laar JM; van der Heijde D; Welsing PMJ
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33419871
[TBL] [Abstract][Full Text] [Related]
13. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
16. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
[TBL] [Abstract][Full Text] [Related]
17. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
[TBL] [Abstract][Full Text] [Related]
18. The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation.
Góralczyk A; Kolossa K; Waszczak-Jeka M; Adamczak R; Jeka S
Postepy Dermatol Alergol; 2020 Jun; 37(3):306-312. PubMed ID: 32774212
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics.
Romão VC; Ávila-Ribeiro P; Gonçalves MJ; Cruz-Machado R; Guerreiro AB; Teixeira V; Valido A; Silva-Dinis J; Vieira-Sousa E; Saavedra MJ; Sacadura-Leite E; Marinho RT; Fonseca JE
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38056920
[TBL] [Abstract][Full Text] [Related]
20. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
